Focus Clinical Scientist

What could make immune-cold tumors responsive to immunotherapy? At #ESMO26, Dr. Sebastian Kobold explores cell therapy and precision patient selection. Watch the full interview: hwisemed.cn/global/stories/t… #Immunotherapy #SolidTumors #Oncology #CancerResearch #Cancer

How can we optimize perioperative immunotherapy without overtreatment? At #ESMO26, Dr. @AndreaNecchi discusses treatment de-escalation, bladder preservation, and new evidence for penile cancer. 📹Watch the full interview. #BladderCancer #PenileCancer #Immunotherapy #Oncology

How can treatment de-escalation reduce long-term toxicity while preserving cure rates? At #ESMO26, Dr. Patrizia Giannatempo @giannatempopatr discusses patient selection and precision-guided treatment. Watch the full interview: hwisemed.cn/global/stories/d… #Oncology #CancerCare #ctDNA

Can personalized cell therapies reshape melanoma treatment? At #ESMO26, Dr. Andrew Furness @ajsfurness discusses TIL therapy, TCR targeting strategies, and biomarker-guided treatment sequencing. Watch the full interview. #Melanoma #Immunotherapy #CellTherapy #SkinCancer

Which biomarkers guide treatment sequencing in gastric cancer? At #ESMO26, Prof. Yelena Y. Janjigian @YJanjigianMD discusses MSI, HER2, CLDN18.2, and emerging combination strategies. Watch the full interview. #GastricCancer #ADCs #GIOncology #Immunotherapy #Biomarkers

Can radiation-based combinations advance conversion therapy in HCC? At #ESMO26, Prof. Laura Dawson @ldawsonmd discusses SBRT, immunotherapy, and transplantation. 🎥Watch the video: hwisemed.cn/global/stories/r… #HCC #LiverCancer #Radiotherapy #Immunotherapy #SBRT

Can personalized vaccines help prevent kidney cancer recurrence? At #ESMO26, Prof. David Braun @BraunMDPhD discusses early Phase 1 findings in high-risk ccRCC and future combination strategies. Watch the full interview. #RenalCellCarcinoma #KidneyCancer #Immunotherapy

Two or three cycles of neoadjuvant therapy for resectable lung squamous cell carcinoma? Dr. Haiquan Chen explores perioperative treatment de-escalation. Read more: hwisemed.cn/global/stories/d… #LungCancer #NSCLC #Immunotherapy #ThoracicSurgery

Can perioperative apalutamide plus ADT improve outcomes in high-risk prostate cancer? At #ESMO26, Prof. @Albert0Briganti discusses PROTEUS findings and the search for biomarkers to guide treatment. 🎥Watch the full interview. #ProstateCancer #Urology #Genitourinary #Oncology

Can molecular profiling guide immunotherapy in biliary tract cancer? At #ESMO26,Dr. Nilofer S. Azad explores combination strategies and patient selection. 🎞️Watch the full interview. #BiliaryCancer #Immunotherapy #MedTwitter #Oncology

Can surgery improve long-term survival in stage III NSCLC? At #WCLC26, Dr. Qinghua Zhou discusses how neoadjuvant therapy may expand surgical options. Read more: hwisemed.cn/global/stories/l… #LungCancer #NSCLC #ThoracicSurgery #Oncology #CancerResearch

What guides first-line treatment choice in CLL? FOCUS Clinical Scientist spoke with Prof. Stephan Stilgenbauer at #ESMO26 about treatment selection, BTK resistance, and the role of TP53 abnormalities and del(17p). Watch the full interview. #CLL #Hematology #Leukemia

Could ADCs replace chemotherapy as the backbone of breast cancer treatment? At #ESMO26, Prof. Sara Tolaney @stolaney1 explores biomarker-guided treatment, endocrine resistance, and personalized treatment de-escalation. Watch the full interview. #BreastCancer #ADCs #Oncology

A 35% response rate in heavily pretreated KRAS G12D-mutant NSCLC, versus historical rates of 15% or less. What makes QLC1101 promising? Dr. Anwen Xiong discusses the clinical data and next steps. Read more: hwisemed.cn/global/stories/q… #LungCancer #NSCLC #KRASG12D #Oncology

Can a novel bispecific antibody boost the abscopal effect of radiotherapy and immunotherapy? At #WCLC26, Prof. Zhongyi Dong’s team shares promising preclinical findings and new directions in lung cancer research. Read more: hwisemed.cn/global/stories/c… #LungCancer #Oncology #NSCLC

Similar symptoms, different mechanisms and treatment strategies. How can clinicians distinguish radiation pneumonitis from immune-related pneumonitis? Dr. Yaping Xu explores key clinical insights at #WCLC26. Read more: hwisemed.cn/global/stories/l… #LungCancer #NSCLC #ThoracicOncology

How is the role of surgery evolving across the lung cancer care continuum? At #WCLC26, Dr. Wentao Fang discusses China's growing research impact and advances in minimally invasive surgery. Read more： hwisemed.cn/global/stories/w… #LungCancer #ThoracicSurgery #LCSM #Oncology

How are advances in perioperative therapy reshaping lung cancer care? At #WCLC26, Dr. Shi Yan explores neoadjuvant treatment, MRD-guided risk stratification, and tailored management of ground-glass nodules. Read more: hwisemed.cn/global/stories/p… #LungCancer #Oncology #MRD #Thoracic

Can ADCs reshape the lung cancer treatment landscape? At #WCLC26, Dr. Jie Hu discusses emerging clinical evidence, safety management, biomarker selection, and the global potential of China’s innovative drugs. Read more: hwisemed.cn/global/stories/a… #LungCancer #ADC #Oncology #SCLC

Can real-world evidence bridge the gap between psoriasis treatment guidelines and individualized care？ Prof. Hong Liu shares key insights. Read more: hwisemed.cn/global/stories/P… #Dermatology #Psoriasis #ClinicalResearch #HealthCare